News Releases

Year

May 06, 2021

UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 6, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic

Mar 18, 2021

UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

Achieved Jelmyto ® net product revenue of $8.0 million for the fourth quarter of 2020; $11.8 million in first seven months of commercialization Initiated ATLAS Phase III trial for UGN-102 and actively enrolling patients with low-grade intermediate risk NMIBC Expanded immuno-oncology pipeline with

Mar 18, 2021

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

RTW Investments, LP will provide UroGen with an upfront cash payment of $75 million and will receive tiered future payments based on worldwide annual net product sales of Jelmyto ® and UGN-102, if approved Strategic funding partnership with RTW Investments, LP enables UroGen to further support the

Mar 15, 2021

UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline

Exploratory research at the Johns Hopkins University to study checkpoint inhibitors combined with RTGel ™ in Glioblastoma Multiforme PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 15, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel

Mar 11, 2021

UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

Conference Call and Webcast Scheduled for Thursday, March 18, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 11, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic

Mar 05, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 5, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to

Feb 23, 2021

UroGen Pharma Announces March 2021 Conference Schedule

PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 23, 2021-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in

Jan 13, 2021

UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

Collaboration will focus on UGN-302 as an investigational treatment for high-grade non-muscle invasive bladder cancer PRINCETON, N.J. & HOUSTON --(BUSINESS WIRE)--Jan. 13, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions

Jan 06, 2021

UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 6, 2021-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett , President and Chief Executive Officer,

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on